(Q33150809)

22 July 2017

1 reference

title

Donepezil: a clinical review of current and emerging indications (English)

1 reference

22 July 2017

Gustavo C Román

1

1 reference

22 July 2017

Susan J Rogers

series ordinal

2

1 reference

22 July 2017

language of work or name

English

0 references

publication date

1 January 2004

1 reference

Expert Opinion on Pharmacotherapy

22 July 2017

published in

1 reference

22 July 2017

volume

5

1 reference

22 July 2017

issue

1

1 reference

22 July 2017

page(s)

161-180

1 reference

Memory and cognitive function in man: Does the cholinergic system have a specific role?

22 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

The cholinergic synapse and the site of memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Selective loss of central cholinergic neurons in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Necropsy evidence of central cholinergic deficits in senile dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

The cholinergic hypothesis of geriatric memory dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Effects of physostigmine and lecithin on memory in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Choline chloride effects on memory in the elderly☆

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Cholinesterases colocalize with sites of neurofibrillary degeneration in aged and Alzheimer's brains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Alpha4 but not alpha3 and alpha7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

TREATMENT OF MYASTHENIA GRAVIS WITH PHYSOSTIGMINE

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Central cholinergic systems and cognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Regulation of regional cerebral blood flow by cholinergic fibers originating in the basal forebrain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Stimulation of the nucleus basalis of Meynert increases cerebral cortical blood flow in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Reduced cortical vasodilatory response to stimulation of the nucleus basalis of Meynert in the aged rat and evidence for a control of the cerebral circulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Effects of age on cholinergic vasodilation of cortical cerebral blood vessels in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Cerebral blood flow and oxygen metabolism in senile dementia of Alzheimer's type and vascular dementia with deep white matter changes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

In-vivo measurements of regional acetylcholine esterase activity in degenerative dementia: comparison with blood flow and glucose metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Nucleus basalis (Ch4) and cortical cholinergic innervation in the human brain: observations based on the distribution of acetylcholinesterase and choline acetyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Topography of the Magnocellular Basal Forebrain System in Human Brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Quantitation and three-dimensional reconstruction of Ch4 nucleus in the human basal forebrain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Cholinesterases in the amyloid angiopathy of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Use of paroxetine for the treatment of depression and anxiety disorders in the elderly: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Extrapyramidal side-effect due to drug combination of risperidone and donepezil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Neuroleptic sensitivity to risperidone in Lewy body dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Suxamethonium and donepezil: a cause of prolonged paralysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Donepezil overdose: a tenfold dosing error.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Urinary incontinence: an unrecognised adverse effect with donepezil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

A new clinical scale for the staging of dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Prediction of functional status from neuropsychological tests in community-dwelling elderly individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Alzheimer's disease and related dementias increase costs of comorbidities in managed Medicare.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Mild cognitive impairment: conceptual basis and current nosological status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Evidence that age-associated memory impairment is not a normal variant of aging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Neuropathological stageing of Alzheimer-related changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Vascular dementia revisited: diagnosis, pathogenesis, treatment, and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Subcortical ischaemic vascular dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Stroke, Cognitive Decline and Vascular Dementia: The Silent Epidemic of the 21st Century

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Spectrum of disease in vascular cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Neuropsychological predictors of incident dementia in patients with vascular cognitive impairment, without dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Substance P-like immunoreactivity, choline acetyltransferase activity and cholinergic muscarinic receptors in Alzheimer's disease and multi-infarct dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Cerebral embolization impairs memory function and reduces cholinergic marker enzyme activities in various brain regions in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Long-term time course of regional changes in cholinergic indices following transient ischemia in the spontaneously hypertensive rat brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

The nucleus basalis of Meynert in multi-infarct (vascular) dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Neocortical infarction in subhuman primates leads to restricted morphological damage of the cholinergic neurons in the nucleus basalis of Meynert

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Donepezil as add-on treatment of psychotic symptoms in patients with dementia of the Alzheimer's type

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Invited review: Anticholinesterases: dramatic aspects of their use and misuse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

The pharmacology of donepezil: a new treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Memantine in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

A 12-week, open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Worldwide occurrence of Parkinson's disease: an updated review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Risk of dementia in Parkinson's disease: a community-based, prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Alzheimer's disease and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Dementia associated with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Lewy bodies and response to tacrine in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Donepezil for cognitive impairment in Parkinson's disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Donepezil in the treatment of progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Donepezil use in the treatment of dementia associated with Down syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Donepezil for Down's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Down syndrome and Alzheimer disease: response to donepezil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease--pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Donepezil in the treatment of opioid-induced sedation: report of six cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Nucleus basalis of Meynert pathology in the human brain after fatal head injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Attention and memory dysfunction after traumatic brain injury: cholinergic mechanisms, sensory gating, and a hypothesis for further investigation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Donepezil medicated memory improvement in traumatic brain injury during post acute rehabilitation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Nucleus subputaminalis (Ayala): the still disregarded magnocellular component of the basal forebrain may be human specific and connected with the cortical speech area

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Effects of increased cholinergic activity on naming in aphasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Open-label study of donepezil in chronic poststroke aphasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Learning and memory impairment in patients with temporal lobe epilepsy: relation to the presence, type, and location of brain lesion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

A pilot study of donepezil for memory problems in epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Central cholinergic challenging of migraine by testing second-generation anticholinesterase drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

Three-dimensional structure of a complex of E2020 with acetylcholinesterase from Torpedo californica

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.1.161

21 January 2018

Identifiers

DOI

10.1517/14656566.5.1.161

1 reference

22 July 2017

1 reference